HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC review agenda

This article was originally published in The Rose Sheet

Executive Summary

Proposed rule on convenience size OTC products now targeted for release in September, according to FDA's 1unified agenda published in the Federal Register May 27. Most recent timeline predicted completion in March. NPR on UVA/UVB sunscreen products is slated for December, while earlier estimates had projected an April timeline. Antiperspirant products final action is anticipated in August, while final action on skin protectant products is slated for July and NPR on astringents is planned for September. ANPR for plaque/gingivitis products was released May 29 (see story, p. 3)...

You may also be interested in...



The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

The Quality Lowdown: Import Alert Update

Crude heparin supplier Yibin Lihao headlines list of facilities in 12 countries added to the US FDA’s drug GMP import alert.

Novartis Pharma President Marie-France Tschudin On Inclisiran, Launches And More

Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.

UsernamePublicRestriction

Register

RS011246

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel